Treatment of Hypotension of Prematurity (TOHOP)
Açar sözlər
Mücərrəd
Təsvir
Rationale: Hypotension in the very preterm infant (gestational age [GA] <32wks) is a frequently occurring clinical problem. Although no real consensus has been reached on the definition of hypotension in the very preterm baby, in clinical practice a mean blood pressure (BP) in mmHg lower than the GA age in weeks is considered to be the starting point for anti-hypotensive therapy. However, although an association between neonatal hypotension and mortality and morbidity exists, there is no evidence of causation between hypotension and neonatal mortality and morbidity (including neurodevelopmental outcome at 2 and 3 years of age). In addition, using mean BP alone as the indication of treatment of neonatal cardiovascular compromise without taking into consideration information on the status of tissue perfusion may lead to unnecessary exposure of neonates to forceful vasoactive medications potentially causing harm to these extremely vulnerable patients.
Objective: To compare neonatal mortality and short-term (advanced MRI indices of structural brain injury at 40 weeks' GA) and long-term neurodevelopmental outcomes (Bayley scales of infant development III [BSID-III] at 24 months) between two groups of very preterm infants presenting with hypotension without clinical and laboratory evidence of compromised tissue perfusion during the first 72 postnatal hours (3 days). Hypotension will be defined as the mean BP (in mm Hg) lower than the infant's GA (in weeks). Patients randomized to "Group A" will be treated according to the treatment policy operative in the Neonatal Intensive Care Unit (NICU) of the Wilhelmina Children's Hospital/University Medical Centre Utrecht (UMCU) while "Group B" will receive no cardiovascular support for hypotension unless they have a mean BP lower than the current limit minus 5 mmHg and/or evidence of compromised tissue perfusion and end-organ function and thus meet established criteria (see below).
Study design: A single-centre randomized non-blinded cohort study in the NICU at the UMCU of preterm neonates <30 weeks' gestation during postnatal days 0 to 3.
Study population: All preterm infants with a GA of <30 weeks admitted on day of postnatal life 0 to the NICU at the UMCU. Patients will be managed according to their randomization to Group A or B until the end of postnatal day 3.
Intervention Patients randomized to "Group A" will be treated for hypotension according to the treatment protocol operative in the NICU at the UMCU. Patients randomized to "Group B" will receive no cardiovascular supportive therapy irrespective of their BP value unless their mean BP is >5 mmHg below GA in weeks for 30 minutes and/or they have indirect clinical or direct laboratory evidence of tissue hypoperfusion and/or end-organ dysfunction (i.e. rScO2 is <50% despite optimized ventilatory support and FiO2 administration, plasma lactate >6 mmol/L; and/or urine output <0.6 mL/kg/hour).
As CO2 is the most potent regulator of cerebral blood flow (CBF), it is understandable why changes in arterial CO2 tension (PaCO2) has been associated with increased incidence of peri-intraventricular hemorrhage (PIVH) in preterm neonates with significant hypercapnia and with white matter injury (periventricular leukomalacia; PVL) in preterm neonates with hypocapnia during the immediate postnatal period. Therefore, in the present study, ventilation will be closely followed and PaCO2 values monitored and attempted to be kept within normal limits (40-to-50 mmHg) during the first three postnatal days to control for the potential impact of this confounding variable as far as the primary and secondary outcome measures are concerned (see below).
Main study parameters/endpoints: To determine whether refraining (group B) from anti-hypotensive treatment has a negative, positive or no effect on the composite outcome of mortality and neurodevelopmental outcome (determined by BSID-III) at 24 months of age. Secondary outcome measures will include 1) differences between the groups in the incidence of PIVH during the first 7 postnatal days detected by head ultrasound, 2) differences in the incidence of white matter injury PVL and gray matter injury not detected within the first 7 days by ultrasound using advanced MRI parameters of the brain at the adjusted postmenstrual age of 40 weeks as well as the ability to maintain CBF autoregulation during the first three postnatal days.
Tarixlər
Son Doğrulandı: | 04/30/2015 |
İlk təqdim: | 09/08/2011 |
Təxmini qeydiyyat təqdim edildi: | 09/12/2011 |
İlk Göndərmə: | 09/13/2011 |
Son Yeniləmə Göndərildi: | 05/25/2015 |
Son Yeniləmə Göndərildi: | 05/26/2015 |
Həqiqi Təhsilin Başlama Tarixi: | 08/31/2011 |
Təxmini İlkin Tamamlanma Tarixi: | 08/31/2016 |
Təxmini İşin Tamamlanma Tarixi: | 08/31/2016 |
Vəziyyət və ya xəstəlik
Müdaxilə / müalicə
Other: Anti-hypotensive treatment
Faza
Qol Qrupları
Qol | Müdaxilə / müalicə |
---|---|
Active Comparator: Standard care Infants will be treated according to the treatment policy operative in the Neonatal Intensive Care Unit (NICU) of the Wilhelmina Children's Hospital/University Medical Centre Utrecht (UMCU): anti-hypotensive therapy will be started when the mean blood pressure (in mmHg) is below the gestational age in weeks. | |
Other: Delayed intervention Anti hypotensive therapy will be started when the mean blood pressure (in mmHg) is < (gestational age in weeks - 5 mmHg) or when there is clinical or biochemical evidence of impaired tissue perfusion. |
Uyğunluq Kriteriyaları
Təhsil üçün uyğun yaşlar | 24 Weeks Üçün 24 Weeks |
Təhsilə Uyğun Cinslər | All |
Sağlam Könüllüləri qəbul edir | Bəli |
Kriteriyalar | Inclusion Criteria: - Idiopathic arterial hypotension as defined by a mean BP in mmHg less than the GA in weeks at birth. - Written parental consent Exclusion Criteria: - Prior inclusion indirect clinical or direct laboratory evidence of poor organ/tissue perfusion (plasma lactate >6 mmol/L on two consecutive measurements and/or urine production <0.6 mL/kg/h for a 6-hour period - Clinically and/or microbiologically proven sepsis - Major congenital abnormalities - Postnatal age at the time of the development of systemic hypotension >72 hours - No arterial line for continuously monitoring of blood pressure |
Nəticə
İlkin nəticə tədbirləri
1. Neurodevelopmental outcome assessment using the Bayley Scales of Infant Development III [24 months postnatal age.]
İkincili Nəticə Tədbirləri
1. Incidence of peri-intraventricular haemorrhage [first 7 postnatal days.]
2. Incidence of white matter injury and gray matter injury [adjusted postmenstrual age of 40 weeks]
3. Difference in the ability to maintain cerebral blood flow autoregulation [Determined from start of hypotensive period (expected within 24h postnatal age) until end of hypotensive period (expected average of 72h postnatal age)]
4. Mortality [Duration of follow-up (24 months postnatal age)]
Elm tərəfindən dəstəklənən ən tam dərman bitkiləri bazası
- 55 dildə işləyir
- Elm tərəfindən dəstəklənən bitki mənşəli müalicələr
- Təsvirə görə otların tanınması
- İnteraktiv GPS xəritəsi - yerdəki otları etiketləyin (tezliklə)
- Axtarışınızla əlaqəli elmi nəşrləri oxuyun
- Təsirlərinə görə dərman bitkilərini axtarın
- Maraqlarınızı təşkil edin və xəbər araşdırmaları, klinik sınaqlar və patentlər barədə məlumatlı olun
Bir simptom və ya bir xəstəlik yazın və kömək edə biləcək otlar haqqında oxuyun, bir ot yazın və istifadə olunan xəstəliklərə və simptomlara baxın.
* Bütün məlumatlar dərc olunmuş elmi araşdırmalara əsaslanır